50% off Premium Yearly

TSE:VMD
VMD EPS of 4c beat estimates of 3.5c; Revenue of $39.6M beat estimates of $38.5M. EBITDA of $8.3M beat estimates by 3%. Sales rose 23%; EPS though was flat year over year. EBITDA rose 15%. 2Q Guidance was maintained and another acquisition was announced. Cash rose to $23.5M (no debt). We would consider it a good quarter.
Unlock Premium - Try 5i Free
He didn't like it for a while, but now more than before. The telehealth space is getting crowded and they've had issues with CMS code. It's a good American company, though doesn't receive much attention here. VMS is merely okay. He prefers other names like Knight Therapeutics. It's a decent, second-tier company.
Viemed Healthcare Inc is a Canadian stock, trading under the symbol VMD.TO (previously VMD-T on Stockchase) on the Toronto Stock Exchange (VMD-CT). It is usually referred to as TSX:VMD or VMD.TO
In the last year, no analyst issued a Buy, Sell, or Hold rating on VMD.TO (previously VMD-T on Stockchase) on Stockchase. Read the latest expert commentary for Viemed Healthcare Inc.
Viemed Healthcare Inc was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Viemed Healthcare Inc.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Viemed Healthcare Inc.
Viemed Healthcare Inc is covered by Stockchase experts and is worth watching.
On 2023-12-21, Viemed Healthcare Inc (VMD.TO) stock closed at a price of $10.45.
Their numbers continues to soar, but shares fell last year over concerns that the hit diet drugs will impact them. But business continues to bs strong as they grow revenues and earnings. Trades at a reasonable PE.